| This week's sponsor is ExL Events. | |  | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Tuesday, September 4, 2018 A scientist who worked at GlaxoSmithKline’s R&D unit in Philadelphia has pleaded guilty to attempting to steal confidential research and funnel it to conspirators in China. |
|
|
| This week's sponsor is Biotech Primer. | |  | |
Top Stories Of The Week Friday, August 31, 2018 In probably the third Chinese drug scandal in two months after Zhejiang Huahai’s tainted valsartan API and Changchun Changsheng Life Sciences’ fabricated vaccine production data exposé, Fosun Pharma has allegedly falsified a large number of production and testing records. Tuesday, September 4, 2018 In yet another indication of what the burden of Brexit will be for drug manufacturers, Pfizer has said that it has tallied its costs to revise its manufacturing and supply chain at about $100 million. Wednesday, September 5, 2018 Theranos, the one-time Silicon Valley biotech star valued at more than $9 billion, has ultimately run out of money, employees and time. It will formally disband in the coming months, according to an email to shareholders obtained by The Wall Street Journal. Wednesday, September 5, 2018 Sangamo’s big chance to show it has a safe and efficient gene-editing technique to rival CRISPR has come—and the initial response has been a little mixed. Thursday, September 6, 2018 Novartis has inked its deal to sell a big chunk of its Sandoz U.S. business. The deal relieves Novartis of a troubled franchise—including some easy-to-copy generics and several manufacturing plants—while boosting buyer Aurobindo to the second-largest generics player by prescriptions in the U.S. Friday, August 31, 2018 Some cancer cells become resistant to treatments, while others simply grow so fast that drugs can’t keep up with them. Two studies out this week suggest potential methods for treating hard-to-beat tumors by targeting the mechanisms by which they survive and proliferate. Friday, August 31, 2018 After the FDA pulled off several nods last week, its European counterpart has matched up with its own party of drug approvals. As Gilead and Novartis won key green lights for their CAR-Ts, Jazz, Ultragenyx and Alnylam also earned their own go-ahead stamps this week. Tuesday, September 4, 2018 Japan’s Fujifilm is investing in Suono Bio’s second-generation drug delivery technology that uses speedy, formulation-independent application of therapeutics that include biologics and gene therapies. Tuesday, September 4, 2018 Pediatric experts have recommended injected vaccines over AstraZeneca's FluMist for the upcoming season. The recommendation from the American Academy of Pediatrics comes after CDC officials endorsed AstraZeneca's nasal vaccine for this year's flu season. Resources Sponsored by: Patheon, part of Thermo Fisher Scientific When developing a parenteral, pharmaceutical scientists are faced with a variety of choices – choices that can be conflicting or present differing advantages. Sponsored by: Baxter Baxter BioPharma Solutions’ whitepaper offers a method to address the challenges of tech transfer for lyophilized products from lab-scale to commercial-scale. Sponsored by: Blue Matter A whitepaper outlining the key commercial challenges facing rare disease products, and how biopharmaceutical companies can overcome them. Sponsored by: AWS and Tableau Inova is using the capabilities of Tableau on AWS to identify biomarkers for personalized treatment intended to improve health outcomes for children. Sponsored by: Catalent In this case study, an unknown leachable species was detected by GC-MS analysis of an alkaline drug product (pH approximately 10.5) that was packaged in a novel self- contained plastic Blow Fill Seal (BFS) vial. Sponsored by: AWS and Reltio Reltio and IQVIA provide holistic data management solutions for traditional pharma, emerging biotech, and consumer health companies, on AWS. Presented by: AWS and Druva Life Sciences organizations are embracing cloud-based Master Data Management (MDM) to modernize the organization of critical data. Sponsored by: Catalent Catalent provides world class stability services to ease your critical path to success. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: Health Strategies Group The window of market exclusivity continues to narrow dramatically in the global marketplace. Given this demanding environment, your global market access team faces increasing urgency to get the value proposition right at the time of launch. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. | 
